Toronto Innovation Acceleration Partners Leads Investment in Northern Vascular Systems to Advance Clinical Development of Novel Light-Activated Embolization Technology TORONTO, ON — July 23, 2026 — Northern Vascular Systems (NVS), a Toronto-based medical device company developing next-generation embolization technologies for neurovascular disorders, and Toronto Innovation Acceleration Partners…
Canada has the science. Does it have the strategy to be a life sciences power? Co-authored by Matthew Carlyle, President and CEO, adMare BioInnovations; Prakash Gowd, Interim CEO, Toronto Innovation Acceleration Partners, Maura Campbell, President and CEO, OBIO; Jason Field, President and CEO, Life Sciences Ontario; Benoît Larose, President and CEO, BIOQuébec; Wendy Hurlburt, President…
Synakis Announces Close of Oversubscribed Pre-Seed Round TORONTO, May 21, 2026 /CNW/ – Synakis Corp., a Toronto-based biotechnology company developing ocular therapies for retinal disease and glaucoma, announced today the close of an oversubscribed CAD $2.6 million pre-seed financing round to advance SNK-125, its vitreous replacement therapy for retinal detachment. Proceeds will support completion…
TIAP is excited to have entered into a new partnership with Mission BioCapital to bring dedicated support from their Platinum Program to biotech start-ups here in Canada’s leading health sciences cluster — significantly enhancing access to the resources needed to turn early-stage innovation into real patient impact and commercial success. For 2026, this global program looks…
TIAP Voices: Why Canadian Digital Health Companies Must Think Globally By: Mobeen Lalani, TIAP Manager, Technology and Venture Development Canadian digital health, artificial intelligence (AI), and medical device companies have long looked south to the United States for growth and validation—thanks to its vast healthcare market, access to capital, and proven track record in adopting innovation.…
A new partnership by MaRS, OBIO® and TIAP aims to help ventures scale faster, attract capital and deliver breakthrough health innovations to the world. TORONTO, October 27, 2025 – Ontario’s life sciences sector is taking a major leap forward with the launch of Life Sciences Central, a new collaborative initiative that brings together the …
TIAP Launches Next Generation Program to Support Early-Stage Drug Development LAB150-NextGen to offer up to $1.6M USD per project to advance new drug candidates May 20, 2025 Building on the success of TIAP’s LAB150 Program, we are pleased to announce a new iteration of the program — LAB150-NextGen to support the advancement and commercialization of…
TIAP Voices: The Venture Building Journey and the Importance of Balanced Investor Engagement by: Mobeen Lalani, TIAP Senior Analyst, Technology and Venture Development In today’s ever-evolving health innovation and business environment, it is more imperative than ever that entrepreneurs are well-supported by investors who not only provide them with those all-important early dollars but remain…
Government of Canada invests in southern Ontario’s life sciences sector From: Federal Economic Development Agency for Southern Ontario News release Six life sciences organizations expand manufacturing capabilities and commercialize innovations February 14, 2025 – Toronto, Ontario Southern Ontario’s life sciences sector is home to first-rate research institutions, cutting-edge companies and a…
Grey Matter Neurosciences Secures License for World-Leading Focused Ultrasound Technology from Sunnybrook Research Institute, Announces $14 Million Financing to Advance Treatment for Alzheimer’s Disease News provided by Grey Matter Neurosciences Jan 23, 2025, 16:13 ET TORONTO, Jan. 23, 2025 /CNW/ – Grey Matter Neurosciences, a neurotechnology company developing medical devices that facilitate…
